Biotech Event Tracker

274 events

Date	Symbol	Description	Type	Disease	Designation	Success Rating
Q1 2017	OMED	OncoMed Pharmaceuticals (OMED) Phase 2 Results of Tarextumab for Small Lung Cancer	Phase 2 Results	Oncology	Orphan Drug
H1 2017	CEMP	Cempra (CEMP) Phase 3 Results of Taksta for Skin Infection	Phase 3 Results	Infectious Disease	None
07/01/2016	INSY	Insys Therapeutics (INSY) PDUFA of Syndros for Anorexia in Patients with AIDS and Nausea/Vomiting Associated with Chemotherapy	PDUFA	Oncology	None
H2 2016	ONCE	Spark Therapeutics (ONCE) Phase 1/2 Results of SPK-CHM for Choroideremia	Phase 1/2 Results	Other	Orphan Drug
H2 2016	LXRX	Lexicon Pharmaceuticals (LXRX) Phase 3 Results of Sotagliflozin for Type 1 and Type 2 Diabetes	Phase 3 Results	Endocrine	None
Q2 2017	VSAR	Versartis (VSAR) Phase 3 Results of Somavaratan for Growth Hormone Deficiency	Phase 3 Results	Endocrine	Orphan Drug
06/01/2016	AAAP	Advanced Accelerator Applications (AAAP) PDUFA of Somakit-TATE for Neuroendocrine Tumors	PDUFA	Oncology	None, Orphan Drug, Priority Review
Q4 2016	ANTH	Anthera Pharmaceuticals (ANTH) Top-line Phase 3 Results of Sollpura (liprotamase) for Exocrine Pancreatic Insufficiency in Patients with Cystic Fibrosis	Phase 3 Results	Endocrine	None
12/28/2016	CEMP	Cempra (CEMP) PDUFA of Solithera for Bacterial Pneumonia	PDUFA	Other	Fast Track
H2 2016	SNGX	Soligenix (SNGX) Phase 3 Results of SGX301 for Cutaneous T-cell Lymphoma	Phase 3 Results	Oncology	Fast Track, Orphan Drug